Supporting Information for

Oxytrodiflavanone A and Oxytrochalcoflavanones A,B: New Biflavonoids from *Oxytropis chiliophylla*

Yang Liu [1], Norbo Kelsang [1], Jianghai Lu [2], Yingtao Zhang [1], Hong Liang [1], Pengfei Tu [1], Dexin Kong [3, 4, *] and Qingying Zhang [1,*]

[1] State Key Laboratory of Natural and Biomimetic Drugs and Department of Natural Medicines, School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing 100191, China;

[2] National Anti-Doping Laboratory, China Anti-Doping Agency, Beijing 100029, China;

[3] Tianjin Key Laboratory on Technologies Enabling Development of Clinical Therapeutics and Diagnostics, School of Pharmacy, Tianjin Medical University, Tianjin 300070, China

[4] Research Center, School of Medicine, Tianjin Tianshi College, Tianyuan University, Tianjin 301700, China

Contents of Supporting Information

Figures

Table



Figure S1. ^{1}H NMR spectrum of oxytrodiflavanone A (**1**) in $CDCl_3$



Figure S2. ^{13}C NMR spectrum of oxytrodiflavanone A (**1**) in $CDCl_3$



Figure S3. ^{1}H-^{1}H COSY spectrum of oxytrodiflavanone A (**1**) in $CDCl_3$



Figure S4. HSQC spectrum of oxytrodiflavanone A (**1**) in $CDCl_3$



Figure S5. HMBC spectrum of oxytrodiflavanone A (**1**) in $CDCl_3$



Figure S6. ^{1}H NMR spectrum of oxytrodiflavanone A (**1**) in Pyridine-d_5



Figure S7. NOESY spectrum of oxytrodiflavanone A (**1**) in Pyridine-d_5



Figure S8. ^{1}H NMR spectrum of oxytrochalcoflavanones A (**2**) and B (**3**) in $CDCl_3$



Figure S9. ^{13}C NMR spectrum of oxytrochalcoflavanones A (**2**) and B (**3**) in $CDCl_3$



Figure S10. ^{1}H-^{1}H COSY spectrum of oxytrochalcoflavanones A (**2**) and B (**3**) in $CDCl_3$



Figure S11. HSQC spectrum of oxytrochalcoflavanones A (**2**) and B (**3**) in $CDCl_3$



Figure S12. HMBC spectrum of oxytrochalcoflavanones A (**2**) and B (**3**) in $CDCl_3$



Figure S13. Targeted MS/MS spectra of oxytrodiflavanone A (**1**), oxytrochalcoflavanones A (**2**) and B (**3**) at CE of 25 eV in negative ion mode



Figure S14. Chiral analysis of oxytrochalcoflavanones A−B (**2-3**)



Figure S15. ^{1}H NMR spectra of the epimers of oxytrochalcoflavanones A−B (**2-3**)



Figure S16. Cell growth inhibitory activities of oxytrodiflavanone A (**1**) and oxytrochalcoflavanone B (**3**) on PC3 cells. The activities of indicated concentrations of Comound 1, Compound 3 and ZSTK474 (postive control) on PC3 cells were determined by MTT assay. Data are presented as mean ± SD, representative of three independent experiments.

Table S1. Raw data of cell growth inhibitory activities of oxytrodiflavanone A (**1**), oxytrochalcoflavanones B (**3**)

Compounds	**Concentration (μM)**	**cell viability (mean ±SD, %)**
1	0.1	98.6 ± 4.0
	0.5	91.4 ± 10.7
	1	93.8 ± 4.1
	5	58.6 ± 5.1
	10	41.3 ± 5.8
	25	4.9 ± 2.9
3	0.1	99.4 ± 12.4
	0.5	95.5 ± 8.1
	1	70.5 ± 0.4
	5	33.8 ± 6.2
	10	29.4 ± 12.1
	25	2.6 ± 4.1
ZSTK474	0.01	90.0 ± 2.5
	0.05	73.0 ± 3.4
	0.1	66.0 ± 4.4
	0.5	47.0 ± 5.1
	1	43.0 ± 6.3
	10	32.0 ± 7.5